X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x -21.1 28.1 - View Chart
P/BV x 2.5 3.3 75.0% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
IPCA LABS
Mar-18
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs149695 21.4%   
Low Rs82400 20.6%   
Sales per share (Unadj.) Rs84.1260.2 32.3%  
Earnings per share (Unadj.) Rs-18.319.0 -96.5%  
Cash flow per share (Unadj.) Rs-6.733.1 -20.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7213.0 39.3%  
Shares outstanding (eoy) m61.25126.20 48.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.1 65.2%   
Avg P/E ratio x-6.328.9 -21.9%  
P/CF ratio (eoy) x-17.216.6 -104.1%  
Price / Book Value ratio x1.42.6 53.7%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m7,07469,120 10.2%   
No. of employees `0002.813.3 20.7%   
Total wages/salary Rs m1,4497,359 19.7%   
Avg. sales/employee Rs Th1,874.12,477.4 75.6%   
Avg. wages/employee Rs Th527.0555.2 94.9%   
Avg. net profit/employee Rs Th-407.7180.6 -225.7%   
INCOME DATA
Net Sales Rs m5,15432,836 15.7%  
Other income Rs m100418 23.9%   
Total revenues Rs m5,25433,254 15.8%   
Gross profit Rs m-7664,505 -17.0%  
Depreciation Rs m7111,777 40.0%   
Interest Rs m1,503240 625.7%   
Profit before tax Rs m-2,8812,905 -99.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17511 3.3%   
Profit after tax Rs m-1,1212,394 -46.8%  
Gross profit margin %-14.913.7 -108.4%  
Effective tax rate %-0.617.6 -3.3%   
Net profit margin %-21.87.3 -298.4%  
BALANCE SHEET DATA
Current assets Rs m3,81019,455 19.6%   
Current liabilities Rs m8,36510,076 83.0%   
Net working cap to sales %-88.428.6 -309.4%  
Current ratio x0.51.9 23.6%  
Inventory Days Days15698 159.0%  
Debtors Days Days6767 100.4%  
Net fixed assets Rs m14,48020,260 71.5%   
Share capital Rs m61252 24.3%   
"Free" reserves Rs m90326,633 3.4%   
Net worth Rs m5,12726,886 19.1%   
Long term debt Rs m5,8322,340 249.2%   
Total assets Rs m19,43341,173 47.2%  
Interest coverage x-0.913.1 -7.0%   
Debt to equity ratio x1.10.1 1,306.8%  
Sales to assets ratio x0.30.8 33.3%   
Return on assets %2.06.4 30.7%  
Return on equity %-21.98.9 -245.6%  
Return on capital %3.610.8 33.8%  
Exports to sales %24.547.6 51.5%   
Imports to sales %10.214.9 68.5%   
Exports (fob) Rs m1,26415,642 8.1%   
Imports (cif) Rs m5254,884 10.7%   
Fx inflow Rs m1,53915,642 9.8%   
Fx outflow Rs m9424,884 19.3%   
Net fx Rs m59710,759 5.6%   
CASH FLOW
From Operations Rs m5993,411 17.6%  
From Investments Rs m-438-1,354 32.3%  
From Financial Activity Rs m-303-1,304 23.2%  
Net Cashflow Rs m-141753 -18.8%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - LUPIN LTD COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS